Castle biosciences stock.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.FRIENDSWOOD, Texas, November 08, 2023--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major …Derek has made over 103 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 600 units of CSTL stock worth 12,060$ on 3 August 2023. 世界市場 道具 ポートフォリオ. Track performance, allocation, dividends, and risks ...Castle Biosciences, Inc. (CSTL) Stock Price | Stock Quote Nasdaq - MarketScreener CASTLE BIOSCIENCES, INC. PDF Report Castle Biosciences, Inc. Stock price …

Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,650 on 14 July 2023.440 units of CSTL stock worth $8,650 on 14 July 2023.Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September ...Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.

11/08/2023 - 01:00 PM. FRIENDSWOOD, Texas -- (BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.

Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,070 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …Castle Biosciences is a leading diagnostic company focused on transforming disease management by keeping people first…. The patients who benefit from the information that our advanced diagnostic tests provide. The clinicians who use our tests to guide disease management decisions. Our talented and valued employees. Our investors.June 11, 2023 at 5:04 AM · 3 min read. Whilst it may not be a huge deal, we thought it was good to see that the Castle Biosciences, Inc. ( NASDAQ:CSTL) Independent Director, Ellen Goldberg ...Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,070 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 7.52% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...

The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical …

It’s estimated that there are over 30,000 castles in Ireland. Some are parts of ruins, some are homes, some are offices — and some castles in Ireland are available for people from all over the world to visit and stay in during their vacatio...The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 1 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 830 units of CSTL stock worth $17,355 on 10 June 2022.830 units of CSTL stock worth $17,355 on 10 June 2022.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results …Studies have shown that using Castle’s DecisionDx®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes1-5 Castle’s...Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months.Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ... 6 Mar 2023 ... Today's Castle Biosciences Inc Share Price - Explore CSTL stock Information, latest price chart, peers growth, market trend and start ...11/08/2023 - 01:00 PM. FRIENDSWOOD, Texas -- (BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this …4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.Castle Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CSTL updated stock price target summary.

The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement ...Derek has made over 103 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 600 units of CSTL stock worth 12,060$ on 3 August 2023. 世界市場 道具 ポートフォリオ. Track performance, allocation, dividends, and risks ...

Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results …Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,653 on 2 June 2023.Jun 5, 2023 · Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months. You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Castle Biosciences, Inc. Common Stock (CSTL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.

Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,820 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …

At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.Nov 2, 2023 · Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide. Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...Materials used to build castles include earth, wood and stone. Motte-and-bailey castles were made of earth and wood, but due to weaknesses in these castles, stone castles were created.Are you yearning for adventure, breathtaking landscapes, and a journey through history? Look no further than a tour of Scotland and Ireland. These two countries boast rich cultural heritage, stunning natural beauty, and countless attraction...News Castle Biosciences Inc. No significant news for in the past two years. Shares Sold Short 1.43 M Change from Last 28.06% Percent of Float 5.52% Stock Money Flow …Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. ... up to an additional $75.0 million in cash and common stock will be payable in connection with the ...Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,650 on 14 July 2023.440 units of CSTL stock worth $8,650 on 14 July 2023.Jun 5, 2023 · S hares of Castle Biosciences (NASDAQ: CSTL) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is ...

Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MCastle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...Jun 5, 2023 · Castle Biosciences (CSTL) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00 . The company’s shares closed last ... Instagram:https://instagram. reviews on molina healthcareauatozonenasdaq nstgtop penny stocks to buy now Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,650 on 14 July 2023.440 units of CSTL stock worth $8,650 on 14 July 2023. jams fast acting chewsgle 63 amg coupe Castle Biosciences Stock Forecast · Over the next 52 weeks, Castle Biosciences has on average historically fallen by 6.5% based on the past 3 years of stock ... fmc okta In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Castle Biosciences Stock Forecast · Over the next 52 weeks, Castle Biosciences has on average historically fallen by 6.5% based on the past 3 years of stock ...Health has made over 7 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Health sold 250,000 units of CSTL stock worth $8,625,000 on 12 May 2020.